Developer docs
API playgroundTry for free, no card

Search company profiles

Oculis

Full company profile

uuid00003wz

Namestring
Oculis
Legal namestring
Oculis Holding AG
Websiteurl
oculis.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Oculis Holding AG is a clinical-stage biopharmaceutical company developing ophthalmic and neuro-ophthalmic therapeutics. Incorporated in Switzerland in 2017 (with predecessor entity dating to 2003) and dual-listed on the U.S. Nasdaq Global Market and Nasdaq Iceland Main Market under ticker OCS, the company is headquartered in Zug, Switzerland, with operating laboratory facilities in Reykjavik, Iceland, and medical affairs activity in the United States. Oculis has no approved products and is currently pre-commercial, with the most recent disclosed quarterly revenue of approximately $0.50M derived from limited operations or collaboration activity rather than product sales.

Short descriptiontext

Oculis Holding AG is a clinical-stage biopharmaceutical company developing topical ophthalmic and neuro-ophthalmic therapeutics, including Privosegtor (OCS-05) for optic neuritis, Licaminlimab (OCS-02) for dry eye disease, and the OCS-01 dexamethasone program, all leveraging the proprietary OPTIREACH® topical delivery platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, topical drug delivery, neuroprotective therapeutics, dry eye disease drugs, retinal disease treatments
Industry3 codes
PRIMARYHLAKAKAE
Retina & Vitreous Specialists
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Ophthalmic Goods3851
Product category
Ophthalmic Biopharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-Revenue / Pre-Commercial Biopharmaceutical Operations
TypeHardware Sales
Description

Oculis is a pre-commercial clinical-stage biopharmaceutical company with no approved products; reported minimal revenue (approximately $0.50 million in a quarter) primarily from limited operations/collaboration. The company's value driver is the late-stage clinical pipeline (Privosegtor, Licaminlimab) intended for eventual commercialization as prescription therapeutics. Once approved, expected revenue would be derived from one-time prescription drug sales (hardware/pharmaceutical product sales) of ophthalmic and neuro-ophthalmic therapies.

seekingalpha.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1OPTIREACH®
Description

Proprietary drug delivery technology platform used to develop topical eye drop formulations, including the OCS-01 dexamethasone cyclodextrin-based ophthalmic solution.

oculis.com
+3 more records
Core offering1 text field

Oculis is a clinical-stage biopharmaceutical company developing a pipeline of topical ophthalmic drug candidates for retinal, neuro-ophthalmic, and ocular surface diseases, anchored by its proprietary OPTIREACH® cyclodextrin-based topical drug delivery platform. The company is currently advancing three lead assets: Privosegtor (OCS-05), a first-in-class neuroprotective peptoid for optic neuritis and NAION; Licaminlimab (OCS-02), an anti-TNFα biologic eye drop for dry eye disease; and OCS-01, a topical dexamethasone for diabetic macular edema and post-cataract surgery inflammation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 7-fold increase in treatment response in TNFR1 biomarker-positive DED patients with Licaminlimab vs. vehicle
+2 more records
Product overview1 text field

Oculis is a clinical-stage biopharmaceutical company offering a single, integrated pipeline of ophthalmic therapeutic candidates rather than a software product suite. Its portfolio is anchored by the proprietary OPTIREACH® topical drug-delivery technology platform, which underpins the company's lead ocular-surface and back-of-the-eye candidates: Privosegtor (OCS-05), a novel peptoid small molecule neuroprotective candidate in development for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION); Licaminlimab (OCS-02), an anti-TNFα eye drop for dry eye disease formulated using OPTIREACH®; and OCS-01, a topical dexamethasone eye drop being evaluated in the DIAMOND Phase 3 program for diabetic macular edema and post-cataract surgery inflammation and pain.

Product and service3 records
1Privosegtor (OCS-05)
CategoryDrug candidate (neuroprotective small molecule)
Description

A first-in-class novel peptoid small molecule (BN201-class) neuroprotective drug candidate in development for acute optic neuritis, non-arteritic anterior ischemic optic neuropathy (NAION), and multiple sclerosis relapses. It crosses the blood-brain and retinal barriers, has received FDA Breakthrough Therapy and EMA PRIME designations, and holds Orphan Drug designations from both FDA and EMA for acute optic neuritis. PIONEER Phase 3 program and PREDICT-1 trial are in progress.

2Licaminlimab (OCS-02)
CategoryDrug candidate (topical biologic)
Description

Anti-TNFα eye drop candidate in development for dry eye disease (DED) and ocular surface inflammation, leveraging the OPTIREACH® delivery platform. A humanized single-chain variable fragment (scFv) antibody neutralizing TNFα with lower molecular weight than a full antibody, paired with a proprietary TNFR1 genetic biomarker enabling 7-fold higher treatment response in biomarker-positive patients.

3OCS-01
CategoryDrug candidate (topical dexamethasone formulation)
Description

Topical dexamethasone eye drop formulation leveraging the OPTIREACH® cyclodextrin-based delivery technology. OCS-01 was being evaluated in the DIAMOND Phase 3 program for diabetic macular edema (DME) and in the OPTIMIZE Phase 3 program for inflammation and pain following cataract surgery. The DME program was discontinued following May 2026 Phase 3 failure.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-to-commercial ophthalmology biopharma (avacincaptad pegol for geographic atrophy) acquired by Astellas for ~$5.9B in 2023; directly comparable late-stage ophthalmology pipeline-stage peer that shared the same SNSP regulatory pathway and was led by executives (Shah) now at Oculis.

TypeDirect peer
Description

Commercial-stage ophthalmology biopharma with Syfovre (pegcetacoplan) for geographic atrophy and Empaveli; a directly comparable back-of-the-eye, complement-mediated disease peer sharing retina specialist channels and KOL relationships.

TypeDirect peer
Description

Clinical-stage ophthalmology biopharma developing tarcocimab and other anti-VEGF therapeutics for retinal diseases including DME; directly comparable late-stage retinal-disease pipeline and similarly dependent on intravitreal-vs-non-invasive paradigm.

TypeDirect peer
Description

Late-stage clinical biopharma focused on dry eye disease and other immune-mediated ocular diseases (reproxalap); directly comparable DED-focused pipeline with similar regulatory pathway and target prescriber base.

TypeDirect peer
Description

Clinical-stage biopharma developing ONS-5010/Lytenava (bevacizumab) for wet AMD and other retinal indications; comparable small-cap ophthalmology pure-play with similar regulatory and capital-raising profile.

TypeDirect peer
Description

Clinical-stage gene therapy company targeting wet AMD and diabetic macular edema (DME) with ADVM-022; directly comparable late-stage retinal disease developer targeting the same anti-VEGF / DME market OCS-01 was pursuing.

TypeDirect peer
Description

Clinical/commercial gene therapy company with ABBV-RGX-314 for wet AMD/diabetic retinopathy and a deep ophthalmology pipeline; comparable late-stage retinal disease peer with NAVXpressAAV platform and overlapping KOL/clinical trial footprint.

TypeEmerging player
Description

Clinical-stage biopharma developing neuroprotective/complement therapies for neuroinflammatory and ophthalmic indications including geographic atrophy; partial overlap with Privosegtor's neuroprotective mechanism and orphan neurology/ophthalmology strategy.

10Santen Pharmaceutical
TypeBroad incumbent
Description

Global Japanese ophthalmology incumbent with broad prescription portfolio in DED, glaucoma, and retinal disease; large established peer against whose franchise Oculis's Licaminlimab and OPTIREACH®-enabled products would compete.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oculis

Ophthalmic Biopharmaceuticalsoculis.com

Oculis Holding AG is a clinical-stage biopharmaceutical company developing topical ophthalmic and neuro-ophthalmic therapeutics, including Privosegtor (OCS-05) for optic neuritis, Licaminlimab (OCS-02) for dry eye disease, and the OCS-01 dexamethasone program, all leveraging the proprietary OPTIREACH® topical delivery platform.

What Oculis does

Oculis Holding AG is a clinical-stage biopharmaceutical company developing ophthalmic and neuro-ophthalmic therapeutics. Incorporated in Switzerland in 2017 (with predecessor entity dating to 2003) and dual-listed on the U.S. Nasdaq Global Market and Nasdaq Iceland Main Market under ticker OCS, the company is headquartered in Zug, Switzerland, with operating laboratory facilities in Reykjavik, Iceland, and medical affairs activity in the United States. Oculis has no approved products and is currently pre-commercial, with the most recent disclosed quarterly revenue of approximately $0.50M derived from limited operations or collaboration activity rather than product sales.

Oculis firmographics

Firmographics
Name
Oculis
Legal name
Oculis Holding AG
Website
https://oculis.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Oculis Holding AG is a clinical-stage biopharmaceutical company developing topical ophthalmic and neuro-ophthalmic therapeutics, including Privosegtor (OCS-05) for optic neuritis, Licaminlimab (OCS-02) for dry eye disease, and the OCS-01 dexamethasone program, all leveraging the proprietary OPTIREACH® topical delivery platform.
Ownership category
akta.pro rank

Oculis industry classification

Industry
Product category
Ophthalmic Biopharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAKAKAE
Retina & Vitreous Specialists
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Ophthalmic pharmaceuticals
  • Topical drug delivery
  • Neuroprotective therapeutics
  • Dry eye disease drugs
  • Retinal disease treatments

Where Oculis is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices4 records

Markets served

Oculis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-Revenue / Pre-Commercial Biopharmaceutical Operations: Oculis is a pre-commercial clinical-stage biopharmaceutical company with no approved products; reported minimal revenue (approximately $0.50 million in a quarter) primarily from limited operations/collaboration. The company's value driver is the late-stage clinical pipeline (Privosegtor, Licaminlimab) intended for eventual commercialization as prescription therapeutics. Once approved, expected revenue would be derived from one-time prescription drug sales (hardware/pharmaceutical product sales) of ophthalmic and neuro-ophthalmic therapies.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Oculis product offering

Product offering

Core offering

Oculis is a clinical-stage biopharmaceutical company developing a pipeline of topical ophthalmic drug candidates for retinal, neuro-ophthalmic, and ocular surface diseases, anchored by its proprietary OPTIREACH® cyclodextrin-based topical drug delivery platform. The company is currently advancing three lead assets: Privosegtor (OCS-05), a first-in-class neuroprotective peptoid for optic neuritis and NAION; Licaminlimab (OCS-02), an anti-TNFα biologic eye drop for dry eye disease; and OCS-01, a topical dexamethasone for diabetic macular edema and post-cataract surgery inflammation.

Product overview

Oculis is a clinical-stage biopharmaceutical company offering a single, integrated pipeline of ophthalmic therapeutic candidates rather than a software product suite. Its portfolio is anchored by the proprietary OPTIREACH® topical drug-delivery technology platform, which underpins the company's lead ocular-surface and back-of-the-eye candidates: Privosegtor (OCS-05), a novel peptoid small molecule neuroprotective candidate in development for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION); Licaminlimab (OCS-02), an anti-TNFα eye drop for dry eye disease formulated using OPTIREACH®; and OCS-01, a topical dexamethasone eye drop being evaluated in the DIAMOND Phase 3 program for diabetic macular edema and post-cataract surgery inflammation and pain.

Differentiator

Problem solved

Functional benefit

Brands

  • OPTIREACH®: Proprietary drug delivery technology platform used to develop topical eye drop formulations, including the OCS-01 dexamethasone cyclodextrin-based ophthalmic solution.
  • Privosegtor (OCS-05)
  • Licaminlimab (OCS-02)
  • OCS-01

Products and services

  • Privosegtor (OCS-05) A first-in-class novel peptoid small molecule (BN201-class) neuroprotective drug candidate in development for acute optic neuritis, non-arteritic anterior ischemic optic neuropathy (NAION), and multiple sclerosis relapses. It crosses the blood-brain and retinal barriers, has received FDA Breakthrough Therapy and EMA PRIME designations, and holds Orphan Drug designations from both FDA and EMA for acute optic neuritis. PIONEER Phase 3 program and PREDICT-1 trial are in progress.
  • Licaminlimab (OCS-02) Anti-TNFα eye drop candidate in development for dry eye disease (DED) and ocular surface inflammation, leveraging the OPTIREACH® delivery platform. A humanized single-chain variable fragment (scFv) antibody neutralizing TNFα with lower molecular weight than a full antibody, paired with a proprietary TNFR1 genetic biomarker enabling 7-fold higher treatment response in biomarker-positive patients.
  • OCS-01 Topical dexamethasone eye drop formulation leveraging the OPTIREACH® cyclodextrin-based delivery technology. OCS-01 was being evaluated in the DIAMOND Phase 3 program for diabetic macular edema (DME) and in the OPTIMIZE Phase 3 program for inflammation and pain following cataract surgery. The DME program was discontinued following May 2026 Phase 3 failure.

Quantifiable outcome

  • 7-fold increase in treatment response in TNFR1 biomarker-positive DED patients with Licaminlimab vs. vehicle
  • +2 more outcomes

Companies that use Oculis

Customer profile

Segments4 records

Ideal customer profiles2 records

Oculis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Oculis partnerships and signals

Strategic signal

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Oculis competitors and assessment

Company assessment

Peers

Direct peers

  • Iveric Bio: Clinical-to-commercial ophthalmology biopharma (avacincaptad pegol for geographic atrophy) acquired by Astellas for ~$5.9B in 2023; directly comparable late-stage ophthalmology pipeline-stage peer that shared the same SNSP regulatory pathway and was led by executives (Shah) now at Oculis.
  • Apellis Pharmaceuticals: Commercial-stage ophthalmology biopharma with Syfovre (pegcetacoplan) for geographic atrophy and Empaveli; a directly comparable back-of-the-eye, complement-mediated disease peer sharing retina specialist channels and KOL relationships.
  • Kodiak Sciences: Clinical-stage ophthalmology biopharma developing tarcocimab and other anti-VEGF therapeutics for retinal diseases including DME; directly comparable late-stage retinal-disease pipeline and similarly dependent on intravitreal-vs-non-invasive paradigm.
  • Aldeyra Therapeutics: Late-stage clinical biopharma focused on dry eye disease and other immune-mediated ocular diseases (reproxalap); directly comparable DED-focused pipeline with similar regulatory pathway and target prescriber base.
  • Outlook Therapeutics: Clinical-stage biopharma developing ONS-5010/Lytenava (bevacizumab) for wet AMD and other retinal indications; comparable small-cap ophthalmology pure-play with similar regulatory and capital-raising profile.
  • Adverum Biotechnologies: Clinical-stage gene therapy company targeting wet AMD and diabetic macular edema (DME) with ADVM-022; directly comparable late-stage retinal disease developer targeting the same anti-VEGF / DME market OCS-01 was pursuing.
  • REGENXBIO: Clinical/commercial gene therapy company with ABBV-RGX-314 for wet AMD/diabetic retinopathy and a deep ophthalmology pipeline; comparable late-stage retinal disease peer with NAVXpressAAV platform and overlapping KOL/clinical trial footprint.

Emerging players

  • Annexon Inc: Clinical-stage biopharma developing neuroprotective/complement therapies for neuroinflammatory and ophthalmic indications including geographic atrophy; partial overlap with Privosegtor's neuroprotective mechanism and orphan neurology/ophthalmology strategy.

Broad incumbents

  • Santen Pharmaceutical: Global Japanese ophthalmology incumbent with broad prescription portfolio in DED, glaucoma, and retinal disease; large established peer against whose franchise Oculis's Licaminlimab and OPTIREACH®-enabled products would compete.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Oculis social profiles

Digital presence

Oculis compliance and trust

Trust signal

Compliance5 records

Oculis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oculis leadership team

Management profile

Number of profiles

Profiles10 records

Oculis subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Oculis funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oculis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oculis

What does Oculis do?

Oculis is a clinical-stage biopharmaceutical company developing a pipeline of topical ophthalmic drug candidates for retinal, neuro-ophthalmic, and ocular surface diseases, anchored by its proprietary OPTIREACH® cyclodextrin-based topical drug delivery platform. The company is currently advancing three lead assets: Privosegtor (OCS-05), a first-in-class neuroprotective peptoid for optic neuritis and NAION; Licaminlimab (OCS-02), an anti-TNFα biologic eye drop for dry eye disease; and OCS-01, a topical dexamethasone for diabetic macular edema and post-cataract surgery inflammation.

Is Oculis a public or private company?

Oculis is a public company. It is classified as public and is currently operating.

When was Oculis founded?

Oculis was founded in 2017. It employs 51 to 100 people.

Where is Oculis based?

Oculis is headquartered in Lausanne, Switzerland, in the Europe region.

How does Oculis make money?

One revenue line is on record: pre-Revenue / Pre-Commercial Biopharmaceutical Operations.

Who are Oculis's main competitors?

Bausch + Lomb is listed as a peer. Direct peers are Iveric Bio, Apellis Pharmaceuticals, Kodiak Sciences, Aldeyra Therapeutics, Outlook Therapeutics, Adverum Biotechnologies and REGENXBIO. Annexon Inc is listed as an emerging player. Santen Pharmaceutical is listed as a broad incumbent.

Does Oculis have an API?

No public API is recorded for Oculis.

What industry is Oculis in?

Oculis's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAKAKAE, Retina & Vitreous Specialists, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHC Wainwright & Co. maintains Oculis Holding at Buy, keeps price target at $39HC Wainwright & Co. maintained Oculis Holding at Buy and kept its price target at $39. The target implies an upside of 411.1% from the Nov 16 close of $7.63.NasdaqOculis Expands Privosegtor Into Multiple Sclerosis Following IND ClearanceOculis received FDA IND clearance for Privosegtor to develop the therapy for acute multiple sclerosis relapses. The company plans to use data from its Phase 2 ACUITY trial and ongoing PIONEER program, with a 3 mg/kg daily dose for five days. Oculis will present further details at an R&D Day on December 8, 2026.Business & FinancialOculis Announces FDA IND Clearance Enabling Acceleration Of Privosegtor Development Program In Acute Multiple Sclerosis RelapsesOculis announced FDA IND clearance for Privosegtor in acute multiple sclerosis relapses, following pre-IND feedback. The company plans an R&D Day on December 8, 2026, to update on the development program. Privosegtor aims to become the first neuroprotective therapy for acute MS relapses.Business & FinancialOculis Announces FDA IND Clearance Enabling Acceleration Of Privosegtor Development Program In Acute Multiple Sclerosis RelapsesOculis announced FDA IND clearance for Privosegtor in acute multiple sclerosis relapses, following pre-IND feedback. The company plans an R&D Day on December 8, 2026, to update on the development program. Privosegtor aims to become the first neuroprotective therapy for acute MS relapses.YahooOculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis RelapsesOculis announced FDA IND clearance for Privosegtor in acute multiple sclerosis relapses, building on its Phase 2 ACUITY trial. The company plans an R&D Day on December 8, 2026, to update on the program. Privosegtor could become the first neuroprotective therapy for acute MS relapses.Stock TitanOculis gets FDA IND clearance for Privosegtor in MSOculis received FDA IND clearance for Privosegtor in acute multiple sclerosis relapses, building on its Phase 2 ACUITY trial results. The company plans an R&D Day on December 8, 2026, to update on the development program. Privosegtor aims to become the first neuroprotective therapy for acute MS relapses.FinancialContent Business PageOculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis RelapsesOculis announced FDA IND clearance for Privosegtor in acute multiple sclerosis relapses, building on positive Phase 2 ACUITY trial results. The company plans an R&D Day on December 8, 2026, to update the development program. Privosegtor could become the first neuroprotective therapy for acute MS relapses.GlobeNewswireOculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis RelapsesOculis announced FDA IND clearance for Privosegtor in acute multiple sclerosis relapses, building on the positive Phase 2 ACUITY trial. The company plans an R&D Day on December 8, 2026, to update on the development program. Privosegtor could become the first neuroprotective therapy for acute MS relapses.Stock TitanOculis reports four directors' RSU transactionsOculis published notifications of managerial transactions relating to the vesting and settlement of restricted stock units previously granted to directors. The notifications cover Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, all dated November 13, 2026.GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesOculis published four notifications on November 13, 2026, covering the vesting and settlement of RSUs granted to directors. The notifications concern Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner.